Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
出版年份 2020 全文链接
标题
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
作者
关键词
-
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-31
DOI
10.1007/s00280-020-04041-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
- (2019) Lu Jiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo
- (2018) Dandan Song et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- ALDH as a Stem Cell marker in solid tumors
- (2018) E Mariel Toledo-Guzman et al. Current Stem Cell Research & Therapy
- Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway
- (2018) Ping Zhang et al. CELL PROLIFERATION
- Ivermectin as an inhibitor of cancer stem‑like cells
- (2017) Guadalupe Dominguez‑Gomez et al. Molecular Medicine Reports
- Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations
- (2017) Holly Matthews et al. PLoS One
- Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress
- (2016) Yingying Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
- (2016) Q. Dou et al. CANCER RESEARCH
- Preservation of the 3D Phenotype Upon Dispersal of Cultured Cell Spheroids Into Monolayer Cultures
- (2016) Vasilij Koshkin et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Biological characteristics of side population cells in a self-established human ovarian cancer cell line
- (2016) ZHENTONG WEI et al. Oncology Letters
- DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis
- (2015) Jinlong Yin et al. BRAIN
- Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
- (2015) Y.-J. Kwon et al. MOLECULAR CANCER THERAPEUTICS
- Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
- (2015) Dobrin Draganov et al. Scientific Reports
- The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer
- (2014) A. Melotti et al. EMBO Molecular Medicine
- Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation
- (2013) Lynae M. Brayboy et al. FERTILITY AND STERILITY
- Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors
- (2012) W Nörenberg et al. BRITISH JOURNAL OF PHARMACOLOGY
- Glutamate-gated Chloride Channels
- (2012) Adrian J. Wolstenholme JOURNAL OF BIOLOGICAL CHEMISTRY
- The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells
- (2010) S. Sharmeen et al. BLOOD
- A Positive Regulatory Role for the mSin3A-HDAC Complex in Pluripotency through Nanog and Sox2
- (2009) Gretchen A. Baltus et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cyclophosphamide and cancer: golden anniversary
- (2009) Ashkan Emadi et al. Nature Reviews Clinical Oncology
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
- Ivermectin: 25 years and still going strong
- (2007) S. Õmura INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started